TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORSThe present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.A method of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof, wherein the compound is:ruxolitinib;ruxolitinib, wherein one or more hydrogen atoms are replaced by deuterium atoms;{ !-{ l-[3-Fluoro-2-(trifluoromethyl)isoticotinoyi]piperidin-4-yi}-3-[4-(7H- pyrrQlo[2,3-d]pyrifflidin-4-yl)-IH-pyrazol-l-yl]azetidin-3-yl}acetonitrile;4- { 3 -(Cyanomethy l)-3 -[4-(7H-pyrrolo[2,3 -djpyri midin-4-y 1)- 1 H-pyrazol- 1 - yl]azetidin-l-yl}-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-l-carboxamide;[3 -[4-(7H-pyrrol o[2,3 -djpyrimi din-4-y !)- 1 H-pyrazol- 1 -y I ] - 1 -( 1 - { [2- (trifluoromethyl)pyrimidin-4-yl]carbonyl}piperidin-4-yl)azetidin-3-yl]acetonitrile;4-[3-(cyanomethyl)-3-(3',5'-dimethyl-lH,rH-4,4'-bipyrazol-l -yl)azetidin-l -yl]- 2, 5-difluoro-N-[(l S)-2,2,2-trifluoro-l -methyl ethyljbenzamide;((2R, 5 S)-5-{2-[(lR)- 1 -hydroxy ethyl]- IH~imidazo[4,5~d]thieno[3,2-b]pyri din- 1- yl}tetrahydro-2H-pyran-2-yl)acetonitrile;3-[l-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7H-pynOlo[2,3-d]pyrimidin-4- y 1 )- 1 H-pyrazol - 1 -y 1 ] propaneni hi 1 e;3-(l-[I,3]oxazoio[5,4-b]pyridin-2-ylpyrrolidin-3-yl)-3-[4-(7H-pynOlo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l -yl]propanenitrile;4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]propyl}piperazin~l-yl)carbonyl]~3-fluorobenzonitrile,4-[(4-{3-cyano-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrrol-l- yljpropyl } piperazin- 1 -y Ijcarbony l]-3 -fluorobenzonitrile;[trans- 1 -[4-(7H-pyrrol o[2,3 -djpyrimi din-4-yl)- 1 H-pyrazol - 1 -y 1 ]-3 -(4- { [2- (trifluoromethyl)pyrimidin-4-yl]carbony!}piperazin-l-yl)cyc!obuty!]acetonitriIe; {trans-3-(4-{[4-[(3-hydroxyazetidin-l-yl)methyl]-6-(trifluoromethyl)pyri din-2- yijoxy }piperidin- 1 -yl)- 1 -[4-(7H-pyirolo[2,3-d]pyrimidin-4-yl)- IH-pyrazol- 1 - yljcyclobutyl ) acetonitrile;{ trans-3 -(4- { [4- { [(2S)-2-(hy droxymethyl)pyrrolidin- 1 -yljmethyl } -6- (trifluoroniethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyriniidin-4- yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile;{trans-3-(4-{[4-{[(2R)-2-(hydroxymethyl)pyrrolidin-l-yl]methyl }-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)- IH-pyrazol-l -yl]cyclobutyl } acetonitrile;4-(4- { 3 -[(dimethyl amino)m ethyl ]-5-fluorophenoxy } piped din- 1 -yi)-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-iH-pyrazol-l-yl]butanenitrile;5-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyriniidin-4-yl)-l H-pyrazol-l- yl]azetidin-l-yl}-N-isopropylpyrazine-2-carboxamide;4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]azetidin-l-yl}-2,5-difluoro-N-[(l S)-2, 2, 2-trifluoro-l -methyl ethyljbenzamide;5-{3-(cyanomethyl)-3-[4-(lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l- yljazetidin- 1 -yl }-N-isopropylpyrazine-2-carboxamide;{ 1 -(cis-4-{[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4- yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l -yl]azetidin-3- yl} acetonitrile;{ 1 -(ci s-4-{ [4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl]oxy}cyclohexyl)-3-[4-(7H-pynOlo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azeti din-3- yl} acetonitrile;{ 1 -(cis-4- { [4-( 1 -hydroxy- 1 -m ethyl ethy i)-6-(trifluoromethyl)pyri din-2 - yljoxy } cyclohexyl)-3 -[4-(7H-pyrrol o[2,3 -djpyrimi din-4-y 1)- 1 H-pyrazol- 1 -yljazeti din-3 - yl}acetonitrile;{ l-(cis-4-{[4-{[(3R)-3-hydroxypyrrolidin-l-yl]methyl}-6-(trifluoroniethyi)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yi)- 1 H-pyrazol- 1 -yljazeti din-3 -yl } acetonitrile; { 1 -(cis-4- { [4-{ [(3 S)-3 -hydroxypyrrolidin- 1 -yljmethyl } -6- (trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pynOlo[2,3-d]pyrimidin-4-yl)- 1 H-py razol - 1 -y 1 ] azeti di n-3 -y 1 } ac etoni tri 1 e,{trans-3-(4-{[4-({[(l S)-2-hydroxy-l-methylethyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyriniidin-4- yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile;{ trans-3 -(4- { [4-( { [(2R)-2-hy droxypropyl] amino } m ethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile{trans-3-(4-{[4-({[(2S)-2-hydrox;ypropyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy} piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile;{trans-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- 1 -yl]cyclobutyl } acetonitrile; or a pharmaceutically acceptable salt of any of the aforementioned.
JAK 억제제를 사용하는 화농성 한선염의 치료 본 출원은 JAK1 및/또는 JAK2를 억제하는 화합물, 또는 이들의 약학적으로 허용가능한 염의 치료학적으로 유효한 양을 환자에게 투여하는 것을 포함하는, 화농성 한선염의 치료가 필요한 환자에서 화농성 한선염을 치료하는 방법을 제공한다. JAK1 및/또는 JAK2를 억제하는 화합물, 또는 이들의 약학적으로 허용가능한 염의 치료학적으로 유효한 양을 환자에게 투여하는 단계를 포함하는, 화농성 한선염의 치료가 필요한 환자에서 화농성 한선염을 치료하는 방법으로서, 상기 화합물은:룩솔리티닙;하나 이상의 수소 원자가 중수소 원자에 의해 대체된, 룩솔리티닙;{1-{1-[3-플루오로-2-(트리플루오로메틸)이소니코디노일]피페리딘-4-일}-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;4-{3-(시아노메틸)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-1-일}-N-[4-플루오로-2-(트리플루오로메틸)페닐]피페리딘-1-카르복스아미드;[3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]-1-(1-{[2-(트리플루오로메틸)피리미딘-4-일]카르보닐}피페리딘-4-일)아제티딘-3-일]아세토니트릴;4-[3-(시아노메틸)-3-(3',5'-디메틸-1H,1'H-4,4'-비피라졸-1-일)아제티딘-1-일]-2,5-디플루오로-N-[(1S)-2,2,2-트리플루오로-1-메틸에틸]벤즈아미드;((2R,5S)-5-{2-[(1R)-1-하이드록시에틸]-1H-이미다조[4,5-d]티에노[3,2-b]피리딘-1-일}테트라하이드로-2H-피란-2-일)아세토니트릴;3-[1-(6-클로로피리딘-2-일)피롤리딘-3-일]-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]프로판니트릴;3-(1-[1,3]옥사졸로[5,4-b]피리딘-2-일피롤리딘-3-일)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]프로판니트릴;4-[(4-{3-시아노-2-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]프로필}피페라진-1-일)카르보닐]-3-플루오로벤조니트릴;4-[(4-{3-시아노-2-[3-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피롤-1-일]프로필}피페라진-1-일)카르보닐]-3-플루오로벤조니트릴;[트랜스-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]-3-(4-{[2-(트리플루오로메틸)피리미딘-4-일]카르보닐}피페라진-1-일)사이클로부틸]아세토니트릴;{트랜스-3-(4-{[4-[(3-하이드록시아제티딘-1-일)메틸]-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;{트랜스-3-(4-{[4-{[(2S)-2-(하이드록시메틸)피롤리딘-1-일]메틸}-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;{트랜스-3-(4-{[4-{[(2R)-2-(하이드록시메틸)피롤리딘-1-일]메틸}-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;4-(4-{3-[(디메틸아미노)메틸]-5-플루오로펜옥시}피페리딘-1-일)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]부탄니트릴;5-{3-(시아노메틸)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-1-일}-N-이소프로필피라진-2-카르복스아미드;4-{3-(시아노메틸)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-1-일}-2,5-디플루오로-N-[(1S)-2,2,2-트리플루오로-1-메틸에틸]벤즈아미드;5-{3-(시아노메틸)-3-[4-(1H-피롤로[2,3-b]피리딘-4-일)-1H-피라졸-1-일]아제티딘-1-일}-N-이소프로필피라진-2-카르복스아미드;{1-(시스-4-{[6-(2-하이드록시에틸)-2-(트리플루오로메틸)피리미딘-4-일]옥시}사이클로헥실)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;{1-(시스-4-{[4-[(에틸아미노)메틸]-6-(트리플루오로메틸)피리딘-2-일]옥시}사이클로헥실)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;{1-(시스-4-{[4-(1-하이드록시-1-메틸에틸)-6-(트리플루오로메틸)피리딘-2-일]옥시}사이클로헥실)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;{1-(시스-4-{[4-{[(3R)-3-하이드록시피롤리딘-1-일]메틸}-6-(트리플루오로메틸)피리딘-2-일]옥시}사이클로헥실)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;{1-(시스-4-{[4-{[(3S)-3-하이드록시피롤리딘-1-일]메틸}-6-(트리플루오로메틸)피리딘-2-일]옥시}사이클로헥실)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일}아세토니트릴;{트랜스-3-(4-{[4-({[(1S)-2-하이드록시-1-메틸에틸]아미노}메틸)-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;{트랜스-3-(4-{[4-({[(2R)-2-하이드록시프로필]아미노}메틸)-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴{트랜스-3-(4-{[4-({[(2S)-2-하이드록스;이프로필]아미노}메틸)-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;{트랜스-3-(4-{[4-(2-하이드록시에틸)-6-(트리플루오로메틸)피리딘-2-일]옥시}피페리딘-1-일)-1-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]사이클로부틸}아세토니트릴;또는 앞에 언급된 것 중 임의의 약학적으로 허용가능한 염인, 방법.